ProCE Banner Activity

CME

Therapeutic Advances in Myelodysplastic Syndromes: From Investigation to Clinical Practice

Multimedia
In this on-demand webcast from a live symposium, oncology experts Rami S. Komrokji, MD; Amy E. DeZern, MD, MHS; and Amer Zeidan, MBBS, MHS discuss the latest advances in treating myelodysplastic syndromes.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Rami S. Komrokji

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amer Zeidan

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Karyopharm Therapeutics Inc.

Target Audience

This activity is intended for physicians and other healthcare professionals who care for patients with MDS.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate novel therapeutic options for managing MDS-related symptoms, which may include anemia, cytopenia, thrombocytopenia, and/or neutropenia
  • Evaluate available clinical data and emerging treatment options for patients with lower-, intermediate-, or high-risk MDS
  • Plan evidence-based therapeutic strategies for patients with relapsed/refractory disease
  • Identify patients eligible for enrollment on clinical trials investigating novel therapeutic approaches for treating and managing MDS

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from AbbVie, Acceleron, Agios/Servier, Bristol-Myers Squibb/Celgene, Geron, Jazz, Novartis, PharmaEssentia, and Taiho.

Faculty Disclosure

Primary Author

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Bristol-Myers Squibb, CTI BioPharma, Geron, Novartis, and Taiho.

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Amer Zeidan, MBBS, MHS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka Pfizer, Takeda, and Trovagene and consultant/advisor/speaker fees from AbbVie, Acceleron, Amgen, Agios, Aprea, Astellas, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Geron, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie Becker, PhD, has no relevant conflicts of interest to report.

Lisa Kuhns, PhD

Lisa Kuhns, PhD has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD has no relevant conflicts of interest to report.

Brian Purves, PharmD, MBA

Brian Purves has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2022, through June 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners on current and emerging treatment options and the latest clinical data on lower-risk, intermediate-risk, and high-risk MDS.